Who
Carl Aure
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Lifevantage.
In numbers
- Trades disclosed
- 55
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $37K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Nov 2021
- Last trade
- 7 Oct 2026
- Last filed
- 9 Oct 2026
Companies traded
Activity over time
1 Jun 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Oct 2026filed 9 Oct 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code A | —35,749 at $0.00 | filing |
| 7 Oct 2026filed 9 Oct 2026 | LFVN Lifevantageoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,623 at $0.00 | filing |
| 1 Oct 2026filed 5 Oct 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $2,870460 at $6.24 | filing |
| 10 Sep 2026filed 14 Sep 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $12K1,869 at $6.37 | filing |
| 10 Sep 2026filed 14 Sep 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $12K1,869 at $6.37 | filing |
| 1 Jul 2026filed 6 Jul 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $8,5061,361 at $6.25 | filing |
| 1 Jul 2026filed 6 Jul 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $8,5061,361 at $6.25 | filing |
| 1 Apr 2026filed 3 Apr 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $6,4131,527 at $4.20 | filing |
| 1 Apr 2026filed 3 Apr 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $6,4131,527 at $4.20 | filing |
| 1 Jan 2026filed 5 Jan 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $9,4061,527 at $6.16 | filing |
| 1 Jan 2026filed 5 Jan 2026 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $9,4061,527 at $6.16 | filing |
| 1 Oct 2025filed 3 Oct 2025 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $13K1,361 at $9.56 | filing |
| 31 Aug 2025filed 3 Sep 2025 | LFVN Lifevantageoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,792 at $0.00 | filing |
| 31 Aug 2025filed 3 Sep 2025 | LFVN Lifevantageoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,886 at $0.00 | filing |
| 31 Aug 2025filed 3 Sep 2025 | LFVN LifevantageBiotechnology | SEC FORM 4 Code M | —14,792 at $0.00 | filing |
| 31 Aug 2025filed 3 Sep 2025 | LFVN LifevantageBiotechnology | SEC FORM 4 Code M | —18,886 at $0.00 | filing |
| 31 Aug 2025filed 3 Sep 2025 | LFVN LifevantageBiotechnology | SEC FORM 4 Code F | $218K16,610 at $13.10 | filing |
| 26 Aug 2025filed 28 Aug 2025 | LFVN Lifevantageoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,361 at $0.00 | filing |
| 26 Aug 2025filed 28 Aug 2025 | LFVN LifevantageBiotechnology | SEC FORM 4 Code A | —10,241 at $0.00 | filing |
| 1 Jul 2025filed 3 Jul 2025 | LFVN Lifevantageoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,401 at $0.00 | filing |
News
LifeVantage Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)LFVN · manilatimes.net · 12 Oct 2026
0 headlines in the last 90 days name Carl Aure; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.